Clinical trial NCT05265208: Selective Internal Radiation Therapy and Capecitabine (Chemotherapy) Treatment for Liver Cancer
Official title: A Multicenter Open-label Randomized Controlled Prospective Phase II Study Evaluating the Efficacy of Selective Internal Radiation Therapy (Yttrium-90 Glass Microspheres) Combined With Capecitabine in the Neoadjuvant Setting of Operable Intrahepatic CHOlangiocarcinoma
Study type: INTERVENTIONAL
Overall status: SUSPENDED
Phase: PHASE2
Conditions: Resectable Intrahepatic Cholangiocarcinoma
Keywords: Selective Internal Radiation Therapy
Lead sponsor: Center Eugene Marquis
Sponsor class: OTHER
First posted: 2022-03-03
Enrollment: 62
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Treatment of intrahepatic cholangiocarcinoma (ICC) remains difficult. Many patients have unresectable tumors, and survival after resection was only slightly improved with the use of adjuvant capecitabine. One of the major prognostic factors is the resection margin, patients with invaded (R1) or narrow (\<5mm) margins having a higher risk of recurrence.

Selective Internal Radiation Therapy (SIRT) with Yttrium-90 microspheres (also known as SIRT) is an interesting treatment in unresectable ICC. In a phase 2 study, the investigators showed a response rate of 39% and a disease control rate of 98%. Interestingly, 9 of the 41 patients were able to see their tumors downstages to surgery. It was also recently suggested in a retrospective study that patients resected after SIRT had a better prognosis than patients that could be operated upfront, despite less favorable initial tumor characteristics.

Given the absence of validated neoadjuvant treatment, the promising activity of SIRT and chemotherapy combination in the unresectable setting, and the prognostic significance of close surgical margins, the aim of this trial is therefore to study this combination treatment in the neoadjuvant setting of resectable ICC.

Detailed description: The study plans to randomized eligible and consent patients in two balanced parallel groups, the one defined as the experimental arm while the second consisting in the actual standard of care is defined as the control standard arm.

The experimental arm consists in 12 weeks of capecitabine combined with SIRT as neoadjuvant treatment followed by surgery. After SIRT, patients will be assessed at 10 weeks with thoracic-abdominal and pelvic CT scan and liver MRI. If the tumour is still deemed resectable, surgery will be performed at 16 weeks.

In case of discovery of contra-indication to SIRT after inclusion (such as described in the SIRT exclusion criteria section) patients will stop chemotherapy and proceed to surgery within one month. The concerned patients are still included in the study and continue the post-surgery follow-up as expected by the protocol.

In the control arm, patients will proceed to upfront surgery.

The follow - up period begins just after the surgery in both arm, and the patients are evaluated every 3 months for 2 years, then every 6 months for 3 additional years, clinically by an oncologist and radiologically with thoracic-abdominal and pelvic CT scan.

Whether progression occurred, patients will no longer be followed according to the protocol; only vital status continues to be collected until the end of the study (i.e. the last visit of the last patient).

Eligibility criteria: Inclusion Criteria:

1. Age \> 18 years-old,
2. ECOG Performance Status \<2,
3. Histologically-proven ICC,
4. No previous treatment for ICC,
5. Tumour deemed resectable by a hepatobiliary surgeon, validated by a Surgical Review Board,
6. Significant risk of close margins, defined as:

   1. Resection margin predicted by the surgeon \<1 cm
   2. Tumour \>5 cm
   3. Multifocal lesion deemed resectable, validated by a Surgical Review Board
7. Registration with a social security scheme,
8. Patient information and signature of informed consent or legal representative.

Non-inclusion Criteria:

1. Severe fibrosis (F3) ou cirrhosis (F4),
2. Inadequate haematological, hepatic, renal and coagulation functions:

   1. Haemoglobin ≤ 8,5 g/dl
   2. Neutrophils \< 1,5 Giga/L
   3. Platelets \< 60 Giga/L
   4. Bilirubin \> 34 µmol/L
   5. ASAT/ALAT \> 5 x ULN
   6. Creatinine clearance \< 30 ml/min (MDRD)
   7. TP et INR \> 2,3 ULN
   8. TCA \> 1,5 x ULN
3. Uracil blood level \>16 ng/mL,
4. Respiratory insufficiency,
5. Comorbidity precluding surgical resection, such as severe heart disease,
6. Presence of microvacuolar steatosis \> 60% or regenerative nodular hyperplasia, for patients for whom a major hepatectomy is planned,
7. Contraindication to hepatic artery catheterization (vascular abnormalities, bleeding diathesis),
8. Previous chemotherapy (including for another cancer),
9. Previous abdominal (supra-mesocolic) radiotherapy (including for another cancer),
10. Other invasive malignancies,
11. Patient participate to an interventional study that tests another medical intervention before surgery,
12. Pregnant woman or likely to be or breastfeeding, or male or female patients of reproductive potential without effective contraception from screening to 30 days after the end of the treatment adjuvant,
13. Minors, individual deprived of liberty, or under any kind of guardianship,
14. Patients unable to submit to medical follow-up of the study for social, medical or psychological reasons.

Exclusion Criteria:

1. Pulmonary shunt with dose \>30Gy,
2. Digestive shunting, non-correctible by interventional radiology,
3. Absence of fixation of MAA in the tumour.

Primary outcomes:
measure: Frequency of subjects with adequate surgical margins
timeFrame: through study completion, an average of 5 year
Secondary outcomes:
Other outcomes:
Locations:
city: Rennes
country: France
facility: Centre de Lutte contre le Cancer Eugène Marquis
state: Bretagne
city: Clichy
country: France
facility: Hôpital Beaujon
state: Ile-de-France
city: Créteil
country: France
facility: Hôpital Henri - Mondor
state: Ile-de-France
city: Pessac
country: France
facility: Groupe SUD-Haut-Lévêque - Centre Hospitalier Universitaire de Bordeaux
state: Nouvelle Aquitaine
city: Montpellier
country: France
facility: Centre Hospitalier Universitaire de Montpellier
city: Poitiers
country: France
facility: Centre Hospitalier Universitaire de Poitiers
city: Villejuif
country: France
facility: Gustave Roussy
Study officials:
affiliation: Centre de Lutte contre le Cancer Eugène Marquis
name: Julien Edeline, MD
role: PRINCIPAL_INVESTIGATOR
References: